July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Guilherme Nader Marta: We Break Down the Data and Its Implications of Inavolisib Triplet Approval
Jul 4, 2025, 18:03

Guilherme Nader Marta: We Break Down the Data and Its Implications of Inavolisib Triplet Approval

Guilherme Nader Marta, Advanced Clinical Fellow at Dana-Farber Cancer Institute, shared on X:

“Inavolisib triplet approval marks real progress for patients with PIK3CA-mut HR+ mBC

With progress come new questions – on patient selection, toxicity and integration into practice

In this article we break down the data and its implications.”

Title: Inavolisib-Based Triplet Therapy for PIK3CA-Mutated Hormone Receptor+/HER2- Breast Cancer: Clinical Implications and Practical Considerations

Authors: Guilherme Nader-Marta, Sara M. Tolaney, Erica L. Mayer

Guilherme Nader Marta